Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends its …
Biossil takes worldwide control of the CD40 agonist while Alligator retains milestone and royalty exposure and ends its …
Pozdeutinurad produced significant and durable urate lowering in uncontrolled gout, with treatment-emergent adverse-event rates close to placebo
The investigational triple agonist matched semaglutide on average glucose reduction and delivered roughly twice the percentage weight loss …
Interim Phase 1b/2a results showed durable swallowing improvements at the low dose and larger three-month gains at the …
The August 11 operating report puts clinic growth, NeuroStar utilisation and cost discipline at the centre of the …
The August 11 agreement gives Sentynl a route to license the oral neutrophil elastase inhibitor while Mereo advances …
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor …
Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully …
Already a subscriber? Log in